en · de · es · pt
melanotan-2-notes.peptides8425.com › Data › Melanotan-2 Identity And Receptor Pharmacology — Questions and Answers

Melanotan-2 Identity And Receptor Pharmacology — Questions and Answers

By Editorial Desk · published 2025-11-10 · last reviewed 2025-12-26 · Data

Everything below concerns melanogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-12-26. Where a claim depends on a specific study, the study is described rather than over-claimed.

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan-2 at a glance

PropertyValueNotes
Common synonymsMelanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amideNaming follows peptide convention; the numeral distinguishes it from melanotan-1
Molecular formulaC50H69N15O9Includes the lactam bridge; no counter-ion assumed
Monoisotopic mass1023.53 DaFree base; salts and counter-ions shift the observed value
AppearanceWhite to off-white lyophilised powderBatch-to-batch colour variation is not itself proof of impurity
Typical analytical methodRP-HPLC purity determination with ESI-MS identity confirmationRetention time alone does not establish sequence identity

Chemistry and Receptor Pharmacology

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Related pages on this site

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Background from the literature

=== Academic career === Bumpus became a Professor of Medicine in the clinical pharmacology division of Johns Hopkins University School of Medicine, with a secondary appointment in the Department of Pharmacology and Molecular Sciences. She started her own laboratory at Johns Hopkins School of Medicine in 2010 as an Assistant Professor of Medicine and Pharmacology, was promoted to Associate Professor in February 2015, and received Professorship in 2020. Bumpus is known for her research on the metabolism of antiviral drugs used to treat HIV-1 and how genetic variations in drug-processing enzymes may impact these drugs' efficacy. She became Hopkins’ inaugural associate dean of institutional and student equity in 2015 and instituted mentoring programs to expand access to resources and opportunities. After holding that role for two years, in July 2017 she transitioned into a role as senior consulting strategist for Academic and Research Diversity, working with the chief diversity officer to develop and implement diversity and inclusion programs across Johns Hopkins School of Medicine. Bumpus received a Presidential Early Career Award for Scientists and Engineers in 2016. In July 2018, she was named as Associate Dean for Basic Research at Johns Hopkins University School of Medicine.

=== Detection in body fluids === Pseudoephedrine may be quantified in blood, plasma, or urine to monitor any possible performance-enhancing use by athletes, confirm a diagnosis of poisoning, or to assist in a medicolegal death investigation. Some commercial immunoassay screening tests directed at the amphetamines cross-react appreciably with pseudoephedrine, but chromatographic techniques can easily distinguish pseudoephedrine from other phenethylamine derivatives. Blood or plasma pseudoephedrine concentrations are typically in the 50 to 300 μg/L range in persons taking the drug therapeutically, 500 to 3,000 μg/L in people with substance use disorder involving pseudoephedrine or poisoned patients, and 10 to 70 mg/L in cases of acute fatal overdose.

The Bailey peptide synthesis is a name reaction in organic chemistry developed 1949 by J. L. Bailey. It is a method for the synthesis of a peptide from α-amino acid-N-carboxylic acid anhydrides (NCAs) and amino acids or peptide esters. The reaction is characterized by short reaction times and a high yield of the target peptide. The reaction can be carried out at low temperatures in organic solvents. The residues R1 and R2 can be organic groups or hydrogen atoms, R3 is the used amino acid or peptide ester: The reaction mechanism is not known in detail. Supposedly, the reaction begins with a nucleophilic attack of the amino group on the carbonyl carbon of the anhydride group of the N-carboxylic acid anhydride (1). After an intramolecular proton migration, a 1,4-proton shift and the cleavage of carbon dioxide follows, resulting in the peptide bond in the final product (2):

by Night, aired from 2018 to 2021. L.A. by Night is set in the aftermath of the events of Bloodlines, and features characters from the game. Initially developed by Geek & Sundry, Paradox took over production in 2020 for the show's fourth and fifth seasons.

A 2014 Cochrane review found tentative evidence that people treated with sulfonylureas have fewer non-fatal cardiovascular events than those treated with metformin (RR 0.7) but a higher risk of severe hypoglycemia (RR 5.6). There was not enough data available to determine the risk of mortality or of cardiovascular mortality. The FDA requires sulfonylureas to carry a label warning regarding increased risk of cardiovascular death. A 2020 Cochrane systematic review comparing metformin monotherapy to sulfonylureas did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease. Second-generation sulfonylureas have increased potency by weight, compared to first-generation sulfonylureas. Similarly, ACCORD (Action to Control Cardiovascular Risk in Diabetes) and the VADT (Veterans Affairs Diabetes Trial) studies showed no reduction in heart attack or death in patients assigned to tight glucose control with various drugs.

Sources: en.wikipedia.org

Further detail

In April 2012, the Xinjiang Border Defense Corps Female Special Service team (新疆公安边防总队女子特勤分队) was founded. In March 2015 it was renamed to the "Snowy Eagle Female Special Service team" (雪鹰女子特勤分队) at the Xinjiang Border Corps Training Base. At its founding in 2012, it only had 6 members, and by March 2015 it had 34 members. It assisted in security at the China Eurasia Expo multiple times. The Shenzhen Border Defense Detachment operated the Maritime Special Service Team (Nicknamed "Maritime Jiaolongs"), a police tactical unit which is dedicated to maritime anti-terrorism, search and rescue, combat diving and VBSS.

Their size: Varies from a handful of researches to several hundred. The division of labor: Work divided among those working in the laboratory and all other professions involved in the course of the research, ranging from approving committees to designers, technicians, and researchers. The coordination mechanisms: Which includes the formalization of objectives and tasks; the standardization of procedures (protocols, project management, quality management, knowledge management), the validation of publications and cross-cutting activities (number and type of seminars). There are three main factors that contribute to the organizational form of a laboratory :

A phylogenomic and geochemical analysis of proteins plausibly traced to the LUCA shows that the ionic composition of its intracellular fluid is identical to that of hot springs. The LUCA likely was dependent upon synthesized organic matter for its growth. Experiments show that RNA-like polymers can be synthesized in wet-dry cycling and UV light exposure. These polymers were encapsulated in vesicles after condensation. Potential sources of organics at hot springs might have been transported by interplanetary dust particles, extraterrestrial projectiles, or atmospheric or geochemical synthesis. Hot springs could have been abundant in volcanic landmasses during the Hadean.

Drugging a nation, the story of China and the opium curse; a personal investigation, during an extended tour, of the present conditions of the opium trade in China and its effects upon the nation. New York, Chicago [etc.] : F. H. Revell company. Morewood, Samuel (1838). A philosophical and statistical history of the inventions and customs of ancient and modern nations in the manufacture and use of inebriating liquors; with the present practice of distillation in all its varieties: together with an extensive illustration of the consumption and effects of opium, and other stimulants used in the East, as substitutes for wine and spirits. Dublin, W. Curry and W. Carson. William Muir (1875), The opium revenue: Sir William Muir's minute and other extracts from papers published by the Calcutta government; also extracts from parliamentary papers (1st ed.), London: The Anglo-Oriental Society for the Suppression of the Opium Trade, p. 30, Wikidata Q19095804 Musto, David F. The American Disease: Origins of Narcotic Control. New York: Oxford University Press, 1987. Nye, Gideon (1873). The morning of my life in China: comprising an outline of the history of foreign intercourse from the last year of the regime of honorable East India Company, 1833, to the imprisonment of the foreign community in 1839. Ouchterlony, John (1844). The Chinese war: an account of all the operations of the British forces from the commencement to the Treaty of Nanking. London: Saunders and Otley. Peters, Gretchen. Seeds of Terror: How Heroin is Bankrolling the Taliban and Al Qaeda, Thomas Dunne Books (2009).

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

How does it differ from the natural hormone?

The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.

Does it hold any regulatory approval?

No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.

Is melanotan II an approved medication?

No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.

Network